Seattle Genetics
Medical Science Liaison - Texas South Central
Medical Affairs - US Field Based
Description
Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative antibody-based therapies for the treatment of cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition to one marketed product, we are advancing a strong product pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients.
Summary
With Seattle Genetics’ mission to rapidly bring practice-changing innovations to the oncology landscape and the recent announcement of positive data in HER2+ metastatic breast cancer, the tucatinib team is expanding its team with new regional MSL positions in support of a growing development program.
The MSL Team is a part of Medical Affairs and consists of field-based scientists that have direct interactions with investigators and key opinion leaders (KOLs) in the field of oncology. The MSLs work cross-functionally with Clinical Development, Commercial and our internal Medical Affairs colleagues to support our products and our advancing pipeline.
Implement KOL field strategy, including KOL identification and engagement. Facilitate scientific discussions in the field and work with in-house and field partners to facilitate ongoing information/clinical data sharing (i.e., new data, competitive information, customer insights, medical communications support) to optimize communications and coordinated activities across the organization. Deliver scientific presentations internally and externally. Compliantly respond to HCP requests for off label information. Execute conference strategy, including staffing of scientific booths at major conferences and regional clinical meetings. Act as a key liaison for all aspects in the support of investigator sponsored trials (ISTs). Support planning and execution of advisory boards. Partner and collaborate effectively with internal business partners, especially with members of the clinical teams, to support corporate trials including trial awareness and education.
Responsibilities:
- Execute scientific presentations in either one-on-one or group settings.
- Effectively communicate feedback from the field within Medical Affairs and to other internal partners.
- Must stay abreast of relevant medical literature in a self-directed manner.
- As needed, collaborate with cross-functional partners within Medical Affairs and across other departments.
Qualifications:
- A minimum of 5 years of biotechnology or hematology/oncology clinical or basic sciences experience.
- An advanced doctoral degree (MD, PhD or PharmD) and prior MSL experience preferred.
- Candidate should have strong presentation / interaction skills and experience in providing evidence based scientific and clinical information to the medical community.
- 50-75% regional travel required. Must reside within region and live within a reasonable distance of a major airport.
- Preferable city location / Region consists of: Boston/New England.
As the leading employer in our industry in the Pacific Northwest, Seattle Genetics is proud to offer a competitive total compensation package as well as a comprehensive benefits program designed to support the whole lives of our employees and their families. Benefits include medical, vision and dental coverage, group and supplemental life insurance, 401(k) with company match, tuition reimbursement, relocation assistance and much more. To learn more about Seattle Genetics, please visit www.seattlegenetics.com.
Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, color, religion, sex, national origin, protected veteran status, or disability status.
Apply:
Seattle Genetics
Seattle Genetics is an Equal Opportunity Employer
Submitted: 11/09/2019
|